SS-31 50 mg

DRAGON PHARMA SS-31

Dragon Pharma SS-31 50 mg represents the cutting edge of performance and longevity optimization, targeting the very foundation of cellular vitality: the mitochondria. Known scientifically as Elamipretide, SS-31 is a revolutionary tetrapeptide engineered to penetrate and stabilize the inner mitochondrial membrane. For athletes, bodybuilders, and fitness enthusiasts pushing their limits, mitochondrial efficiency is everything—it dictates energy output, recovery speed, and resilience to stress. Intense training generates massive oxidative damage that impairs mitochondrial function, leading to fatigue, delayed recovery, and suboptimal performance. Dragon Pharma SS-31 directly counteracts this by protecting these cellular power plants, ensuring they operate at peak capacity. This results in tangible benefits like increased endurance, reduced muscle fatigue, faster post-exercise recovery, and enhanced overall stamina. Beyond performance, SS-31 is a cornerstone of advanced anti-aging and neuroprotective protocols, making it a uniquely versatile tool for those who view their physique and health as a long-term investment. With a potent 50 mg per vial, Dragon Pharma delivers a research-grade compound of exceptional purity, designed for those who seek to optimize from the cellular level upward.

DRUG COMPOSITION

Each vial contains 50 mg of highly purified SS-31 (Elamipretide) acetate. SS-31 is a synthetic, cell-permeable tetrapeptide with the amino acid sequence: D-Arg-Dmt-Lys-Phe-NH2. The "Dmt" denotes 2',6'-dimethyltyrosine, a key modification that enhances its mitochondrial targeting and stability. The acetate salt form ensures optimal solubility and shelf-life. The product is a sterile, lyophilized white powder free from additives, guaranteeing maximum bioactivity upon reconstitution.

PHARMACEUTICAL FORM

Sterile, white to off-white lyophilized (freeze-dried) powder in a multi-dose 2 mL glass vial. The vial is sealed with a bromobutyl rubber stopper and an aluminum flip-off cap to maintain sterility. Requires reconstitution with Bacteriostatic Water or Sterile Saline before subcutaneous or intravenous injection.

PHARMACEUTICAL GROUP AND ATC CODE

SS-31 is classified as a mitochondrial protective agent or a cardioprotective and neuroprotective peptide. It represents a novel class of compounds known as Szeto-Schiller peptides. As an investigational drug, it does not yet have a standard Anatomical Therapeutic Chemical (ATC) classification. Its mechanisms align with agents that could potentially fall under C01E - OTHER CARDIAC PREPARATIONS or N07X - OTHER NERVOUS SYSTEM DRUGS in the future, based on its clinical targets.

PHARMACOLOGICAL PROPERTIES

SS-31's action is elegantly targeted to the mitochondria, the organelles responsible for over 90% of cellular energy (ATP) production.

• Mitochondrial Membrane Stabilization: Its primary mechanism is binding to cardiolipin, a phospholipid found almost exclusively in the inner mitochondrial membrane. Under stress (like intense exercise), cardiolipin can become oxidized and destabilize, leading to mitochondrial permeability transition pore (mPTP) opening, which impairs ATP production and can trigger cell death. SS-31 binds to and protects cardiolipin, preventing this damaging cascade.
• Reduction of Oxidative Stress (ROS): By stabilizing the electron transport chain (where ATP is made), SS-31 dramatically reduces the leakage of reactive oxygen species (ROS)—the harmful free radicals that cause oxidative damage to muscles, neurons, and other tissues post-exercise.
• Enhanced ATP Production: With a more stable and efficient mitochondrial membrane, the electron transport chain functions optimally, leading to increased synthesis of ATP. This translates directly to greater available energy for muscle contraction, protein synthesis, and cellular repair.
• Anti-Apoptotic Effects: By preventing mPTP opening, it inhibits a key pathway of programmed cell death (apoptosis), particularly in energy-demanding cells like cardiomyocytes (heart cells) and neurons.
• Improved Cellular Calcium Handling: Supports better calcium cycling within muscle cells, which is critical for muscle contraction, relaxation, and overall performance.

These properties make SS-31 not just a performance enhancer, but a fundamental cellular protector.

THERAPEUTICAL INDICATIONS

Within the research and performance optimization context, Dragon Pharma SS-31 50 mg is indicated for:

• Endurance & Stamina Enhancement: Increasing work capacity, delaying the onset of fatigue, and improving aerobic and anaerobic performance by maximizing cellular energy output.
• Accelerated Recovery: Reducing muscle soreness (DOMS), inflammation, and oxidative damage post-training, enabling more frequent and intense sessions.
• Mitigation of Overtraining Syndrome: Protecting against the systemic mitochondrial dysfunction and excessive oxidative stress associated with prolonged, intense training blocks.
• Neuroprotection & Cognitive Support: Supporting mitochondrial health in neurons, potentially improving focus, mental clarity, and resilience to stress, and offering protective benefits for long-term brain health.
• Cardiovascular Performance & Health: Supporting the immense energy demands of the heart muscle, potentially improving cardiac efficiency and recovery, especially under athletic stress.
• Comprehensive Anti-Aging & Longevity Protocols: As a foundational agent in stacks aimed at preserving mitochondrial function, reducing age-related cellular decline, and extending healthspan.

DOSES AND METHOD OF ADMINISTRATION

• Reconstitution: Add 1-2 mL of Bacteriostatic Water or 0.9% Sodium Chloride Injection (sterile saline) to the 50 mg vial. Gently swirl until fully dissolved. This yields a concentration of 25-50 mg/mL.
• Standard Research/Athletic Dosage: Clinical and experimental protocols for performance often use doses ranging from 0.5 mg to 2.0 mg per kilogram of body weight, administered via subcutaneous or intravenous injection. A common and effective athletic starting point is 20-40 mg per day. The 50 mg vial provides a 1.25 to 2.5 day supply at this dosage.
• Dosing Frequency: Can be administered once daily, or split into two doses (e.g., AM and PM). For performance, injection 60-90 minutes before training is optimal to coincide with peak mitochondrial activity during exercise.
• Cycle Length: SS-31 is often used in cycles of 4 to 12 weeks. For endurance blocks or intense preparation, 8-week cycles are common. It can also be used in shorter, 2-4 week "peak" cycles before major events. Longer cycles are typical in anti-aging protocols.
• Administration: Subcutaneous injection is standard, effective, and convenient. Intravenous administration (under proper sterile conditions) may provide more immediate systemic distribution but is generally reserved for clinical settings. Intramuscular injection is not typical. Always use aseptic technique.

CYCLE/STACKING

SS-31's role as a cellular energy optimizer makes it a synergistic component in diverse stacks.

• With NAD+ Boosters for Ultimate Cellular Energy: Stack with NAD+ precursors or [MOTS-c 10mg as a mitochondrial-derived peptide] to powerfully upregulate the entire mitochondrial energy production pathway (electron transport chain and sirtuin activity).
• In an Anti-Aging & Longevity Stack: Combine with Epitalon 50 mg for telomere support and GHK-cu 50 mg for tissue remodeling, creating a comprehensive protocol targeting cellular, genetic, and structural aging.
• For Enhanced Recovery from Injury/Training: Pair with healing peptides like TB 500 and BPC 157. SS-31 provides the cellular energy needed to fuel the repair processes these peptides initiate.
• During a Stimulant-Based Cutting Cycle: Use alongside compounds like Clenbuterol or Salbutamol and T3. SS-31 can help protect the heart and muscles from the increased metabolic and oxidative stress induced by these powerful thermogenics.
• For Cognitive & Physical Peak Performance: Stack with nootropic peptides like Semax 5mg and Selank 10 mg for enhanced focus and stress resilience, while SS-31 provides the underlying cellular energy for sustained mental and physical output.

POST CYCLE THERAPY (PCT)

SS-31 does not affect the HPTA axis and is not used for hormonal recovery. However, it can be an extremely valuable supportive agent during PCT. The post-cycle period is metabolically stressful as the body adjusts to fluctuating hormone levels. Incorporating SS-31 (at a dose of 20-30 mg/day for 4-6 weeks) during PCT can help maintain high cellular energy levels, combat fatigue, support recovery from continued training, and provide mitochondrial protection during a potentially catabolic phase. This can help you preserve strength, endurance, and overall vitality as you recover, making it an excellent addition to a holistic PCT protocol that includes SERMs and liver support.

SIDE EFFECTS

SS-31 has demonstrated an excellent safety profile in clinical trials across various doses. Side effects are rare and typically mild.

• Injection Site Reactions: Mild redness, itching, or discomfort at the subcutaneous injection site.
• Transient Flushing or Warmth: Some users report a brief sensation of warmth or flushing shortly after injection, likely due to vasodilation.
• Mild Headache or Dizziness: Very uncommon, and usually transient, potentially related to changes in vascular tone.
• No Significant Systemic Toxicity: Extensive research has shown no evidence of hepatotoxicity, nephrotoxicity, hematological toxicity, or endocrine disruption.

There are no androgenic, estrogenic, or stimulant-like side effects (jitters, anxiety, increased heart rate).

CONTRAINDICATIONS

Contraindications include a known hypersensitivity to SS-31 (Elamipretide) or any component of the formulation. Due to limited safety data, its use is not recommended during pregnancy or breastfeeding. Individuals with severe, uncontrolled hypertension or a history of severe cardiovascular events (e.g., recent myocardial infarction) should use caution and consult a healthcare provider, although SS-31 is being studied for cardioprotection, its effects in acute, unstable conditions are not fully defined.

OVERDOSE

No cases of acute life-threatening overdose have been reported in human trials. Doses many times higher than the recommended range have been used in preclinical studies without lethal effects. In the event of a massive accidental overdose, potential effects could include pronounced hypotension (low blood pressure), dizziness, or flushing due to its vascular effects. Management would involve discontinuation, supportive care, and monitoring of vital signs. The effects are expected to be self-limiting due to the peptide's relatively short half-life.

WARNINGS AND SPECIAL PRECAUTIONS FOR USE

This product is for research purposes only. It is not approved by the FDA for the treatment or enhancement of any condition. Individuals with pre-existing medical conditions, particularly cardiovascular or renal disorders, should seek medical advice before considering use. While SS-31 is cardioprotective in research models, self-administration in the presence of undiagnosed heart conditions is not advised. Always use sterile solvents and impeccable injection technique to prevent infection. Do not share vials or needles. Keep out of reach of children and pets. The long-term effects of high-dose, off-label use in healthy athletes are not fully known.

INTERACTIONS WITH OTHER DRUGS

No clinically significant adverse drug interactions have been identified. SS-31's mechanism is complementary to many compounds:

• Other Mitochondrial Agents/Nootropics: Effects are likely synergistic with compounds like NAD+, CoQ10, PQQ, or nootropics that enhance cerebral metabolism.
• Antihypertensive Medications: Due to its mild vasodilatory potential, there is a theoretical possibility of additive blood pressure-lowering effects when combined with antihypertensive drugs. Monitoring is advised.
• Exercise & Performance-Enhancing Drugs: SS-31 is expected to work synergistically with training and other PEDs by improving the cellular capacity to handle the increased metabolic demand they create.

PRESENTATION, PACKAGING

Dragon Pharma SS-31 50 mg is presented in professional, discreet packaging. Each box contains one 2 mL clear glass vial. The vial is sealed with a medical-grade bromobutyl rubber stopper and a tamper-evident aluminum flip-off cap. The label clearly displays the Dragon Pharma logo, product name "SS-31," strength "50 mg," batch number, expiration date, and storage instructions. Packaging is designed to protect the lyophilized powder from light and moisture.

STORAGE

• Before Reconstitution: Store the sealed vial in a refrigerator at 2°C to 8°C (36°F to 46°F) for long-term stability. For short periods (under 30 days), storage in a cool, dark place below 25°C (77°F) is acceptable. Avoid freezing.
• After Reconstitution: The reconstituted solution should be stored immediately in the refrigerator at 2°C to 8°C (36°F to 46°F). It remains stable and potent for up to 7 days when refrigerated. For optimal potency, use within 3-4 days of reconstitution. Do not freeze the reconstituted solution. Discard if cloudiness or precipitation occurs.

DELIVERY TO THE USA

We provide fast, secure, and discreet shipping to all 50 states. Orders are processed within 24 hours on business days and shipped in plain, non-descript packaging with no external branding. We utilize reliable courier services and provide tracking information upon shipment. Delivery within the continental USA typically takes 3-7 business days. All payment and personal information is secured using advanced encryption protocols.

LEGAL STATUS

SS-31 (Elamipretide) is an investigational peptide drug candidate and is not approved by the U.S. Food and Drug Administration (FDA) for any indication. It is not classified as a controlled substance. This product is sold explicitly for laboratory research purposes as a biochemical reagent. The buyer assumes full responsibility for understanding and complying with all applicable local, state, and federal laws regarding its purchase, possession, and use.

DATE OF LAST TEXT CHECKS

/

NAME AND ADDRESS OF THE MANUFACTURER

Dragon Pharma, Europe

EXTERNAL LINKS

• NIH/PubMed - Foundational research article on SS-31 (Elamipretide) detailing its mechanism of cardiolipin protection and mitochondrial benefits.
• NIH/PubMed - Review on targeting mitochondrial dysfunction with peptides like SS-31 in aging and metabolic disease.

PROFILE

• Chemical name: Elamipretide (D-Arg-2',6'-Dmt-Lys-Phe-NH2) acetate
• Chemical formula: C₃₈H₅₉N₁₁O₆
• Percentage of anabolic activity: 0% (Non-anabolic; supports anabolic processes indirectly via enhanced cellular energy).
• Percentage of androgenic activity: 0% (Non-androgenic).
• Active half life: Approximately 30-60 minutes in plasma, but its biological effects on mitochondrial membranes are prolonged (hours to days).
• Recommended dosage: 20-40 mg administered subcutaneously once or twice daily.
• Acne: None.
• Bloating (water retention): None.
• HBR (High Blood Pressure): May have a mild lowering effect; no hypertensive effect.
• Hepatic toxicity: None reported.
• Aromatization: Does not aromatize.